In normal subjects, glucagon had small, inconsistent effects on glucose utilization versus the C test, with final values of 7.29 +/- 0.87 versus 6.13 +/- 0.85 mg.kg-1.min-1.
In plain wordsIn healthy subjects, added glucagon had small, inconsistent effects on glucose use compared with the same infusions without glucagon.
- Peptide
- Glucagon
- Outcome
- MixedGlucose utilization
- Study
n: not reported in source
- Comparator
- Somatostatin and insulin infusion without glucagon (C test)
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated · infusionAs given in this study (human).
Measurements
- Glucose Rd at end of test
- 6.13 mg.kg-1.min-1
- C test (somatostatin + insulin)
- Glucose Rd at end of test
- 7.29 mg.kg-1.min-1
- G test (somatostatin + insulin + glucagon)
Source sentences
Compared with the C test, maintenance of glucagon level had only small and inconsistent effects on glucose Rd,
3 context sentences(design, population, supporting numbers)
Intralipid infusion resulted, whether glucagon was substituted or not, in a near total suppression of the insulin-induced increase of glucose Rd (Rd at the end of the tests: C test, 6.13 +/- 0.85 mg.kg-1.min-1; G test, 7.29 +/- 0.87 mg.kg-1.min-1; IL test, 3.30 +/- 0.65 mg.kg-1.min-1; IL + G test, 3…
To study the interactions of physiological glucagon and free fatty acids (FFA) concentrations with insulin in the control of glucose metabolism, we determined in normal subjects
in the presence of glucagon and FFA levels either decreased (somatostatin [SRIF] and insulin infusion, C test) or maintained to normal postabsorptive values isolated (SRIF + insulin + glucagon infusion, G test;